Realtime | Geld | Brief | Zeit |
---|---|---|---|
8,110 | 8,180 | 13:04 | |
8,100 | 8,170 | 22.11. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.11. | ADOCIA SA: Number of Shares and Voting Rights of ADOCIA as of October 31st, 2024 | 281 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
30.10. | ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update | 325 | Business Wire | Cash position of €9.3 million as of September 30, 2024
Completion of the Phase 3 study on BioChaperone Lispro expected in December 2024, associated with a $10 million payment by Tonghua... ► Artikel lesen | |
15.10. | ADOCIA Announces Patenting Stable Combinations of GLP-1 and Amylin Analogs for the Treatment of Obesity and Diabetes Using Its BioChaperone Platform | 250 | Business Wire | Adocia has filed patent applications of stable combinations of semaglutide in combination with cagrilintide
BioChaperone CagriSema could be administered with all standard subcutaneous injection... ► Artikel lesen | |
08.10. | Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024 | 261 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
ADOCIA Aktie jetzt für 0€ handeln | |||||
23.09. | ADOCIA Announces Appointment of Mathieu-William Gilbert as Chief Financial Officer | 419 | Business Wire | Valérie Danaguezian, who has held the position of Chief Financial Officer since Adocia's founding in 2005, is leaving the company to focus on a family project
Mathieu-William Gilbert will... ► Artikel lesen | |
20.09. | Number of Shares and Voting Rights of ADOCIA as of August 31st, 2024 | 293 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
19.09. | ADOCIA Announces First Half 2024 Financial Results and Provides a Business Update | 923 | Business Wire | Cash position of €10.3 million as of June 30, 2024
Net loss of €8.9 million as of June 30, 2024, comparable to the same period in 2023
Debt limited to a state-guaranteed loan amounting... ► Artikel lesen | |
30.08. | Number of Shares and Voting Rights of ADOCIA as of July 31st, 2024 | 211 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
29.08. | ADOCIA to Deliver Oral Presentations on AdoShell and AdoGel at EASD Annual Meeting | 368 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions... ► Artikel lesen | |
24.07. | ADOCIA Reports Second Quarter 2024 Financial Results and Provides a Business Update | 306 | Business Wire | Cash position of €10.3 million as of June 30, 2024
Continuation of partnership discussions on M1Pram with Sanofi
BioChaperone Lispro Phase 3 study is on track for completion in December... ► Artikel lesen | |
19.07. | ADOCIA Announces Half Year Report on Adocia's Liquidity Agreement with Kepler Capital Markets | 285 | Business Wire | Regulatory News:
Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30th 2024
Number... ► Artikel lesen | |
11.07. | Number of Shares and Voting Rights of ADOCIA as of June 30th, 2024 | 404 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
10.07. | ADOCIA Announces That Tonghua Dongbao Is Discontinuing One of the Two Partnership Programs: BioChaperone Combo | 242 | Business Wire | Tonghua Dongbao made this strategic decision after re-assessment of its R&D pipeline and considering the recent regulatory and competitive environment changes
Adocia regains full rights... ► Artikel lesen | |
18.06. | ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions | 477 | Business Wire | Exclusive non-clinical data have been selected for presentations at ADA on three of Adocia's innovative programs:
AdoShell, aimed as a curative treatment for people with Type 1 Diabetes... ► Artikel lesen | |
17.06. | Number of Shares and Voting Rights of ADOCIA as of May 31st, 2024 | 240 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
06.06. | ADOCIA Confirms Its Eligibility for the PEA-PME | 284 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
03.06. | ADOCIA Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer | 259 | Business Wire | Mathieu-William Gilbert, Adocia's new Chief Operating Officer, was previously Vice President and General Manager at Novo Nordisk
In his new role, he will oversee Adocia's operations and... ► Artikel lesen | |
23.05. | ADOCIA Announces its Annual Shareholders' Meeting to be Held on June 13th, 2024 in Paris | 518 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
15.05. | Number of Shares and Voting Rights of ADOCIA as of April 30th, 2024 | 427 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
14.05. | ADOCIA Reports First Quarter 2024 Financial Results and Provides a Business Update | 363 | Business Wire | Cash position of €10.2 million as of March 31, 2024, includes proceeds from the March 2024 financing1, featuring:
€2 million invested by three members of management and Vester Finance,... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 108,90 | +0,28 % | Übernahmefantasie und Momentum: BioNTech, Rheinmetall, Vidac Pharma Aktie | BioNTech will seine Pipeline für den Kampf gegen Krebs stärken und die chinesische Biotechfirma Biotheus übernehmen. Dafür legen die Mainzer für das auf die Entwicklung von Therapien für Krebs- und... ► Artikel lesen | |
EVOTEC | 8,500 | -15,59 % | ASML, Defama, Evotec, Mercedes-Benz, Smartbroker, Süss MicroTec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
MEDIGENE | 1,550 | 0,00 % | PTA-News: Medigene AG: Medigene präsentiert Daten zu innovativer IFN-Gamma-Biosensor-Technologie bei SITC 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert Daten zu innovativer IFN-Gamma-Biosensor-Technologie bei SITC 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/12.11.2024/13:00)... ► Artikel lesen | |
BB BIOTECH | 39,300 | +1,68 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
CUREVAC | 2,566 | +0,63 % | CureVac mit BRANDNEUER Prognose: Steht die Aktie jetzt vor einem Kursdebakel - Am Montag fällt die Entscheidung! | ||
QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
MODERNA | 39,575 | +0,18 % | Opening Bell: Bitcoin, Tesla, Moderna, Netflix, Palantir, Nvidia | Vor dem Wochenende ging es für den Dow Jones um 0,7 Prozent abwärts. Auch auf Wochensicht fuhr er Verluste ein, hier gab er 1,3 Prozent ab. Der Nasdaq 100 verlor sogar 2,4 Prozent in der vergangenen... ► Artikel lesen | |
PAION | 0,006 | -23,08 % | Unglaubliche Prognose für Montag setzt Paion Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
VALNEVA | 2,024 | -0,49 % | Unglaubliche Prognose für Montag setzt Valneva Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
AMGEN | 282,65 | -0,05 % | Dividendenbekanntmachungen (18.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0569 EUR ALGOMA CENTRAL CORPORATION CA0156441077 0,19 CAD 0,128 EUR ALLISON TRANSMISSION... ► Artikel lesen | |
NOVAVAX | 8,130 | +0,02 % | NOVAVAX INC - 8-K, Current Report | ||
EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
STRYKER | 369,80 | +0,05 % | Stryker Stock May Gain From Oculan Lighting Platform's Launch | ||
BIOFRONTERA | 2,700 | -0,18 % | PTA-PVR: Biofrontera AG: Mitteilung über Mitteilungspflichten für Inhaber wesentlicher Beteiligungen gemäß § 43 WpHG | DJ PTA-PVR: Biofrontera AG: Mitteilung über Mitteilungspflichten für Inhaber wesentlicher Beteiligungen gemäß § 43 WpHG
Mitteilungspflichten für Inhaber wesentlicher Beteiligungen gemäß § 43 WpHG... ► Artikel lesen | |
BIOGEN | 151,90 | +0,20 % | UCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In Phase 3 PHOENYCS GO Study | WESTON (dpa-AFX) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant... ► Artikel lesen |